An opportunity to do well by doing good
There’s certainly no shortage of interesting and promising biotechnology companies in which you can invest your time, resources and money. Often, however, investors must wait years and sometimes decades to see a return on complex biological or pharmaceutical technologies. FluGen offers an exciting opportunity for investors who want to participate with a mature technology that has the confidence of current investors, an outstanding Board of Directors and Scientific Advisors and most importantly, an expedited timeline for exit.
FluGen’s value proposition lies in the remarkable science that’s behind the REDEE FLU™ influenza vaccine. FluGen’s REDEE FLU™ has reached critical milestones, including successful vetting by the National Institutes of Health, where testing indicates that REDEE FLU™ is successful in fighting the deadliest of flus. Additionally, FluGen recently received overwhelmingly positive feedback from World Health Organization’s [WHO] scientific community, many of whom commented that FluGen’s data is the best they’ve seen to date.
It is this promising data and test results that position us to plan for human trials in just a few short months, in fall of 2013. With expected successful outcomes, FluGen will be on track to submit to the U.S. Food and Drug Administration [FDA] by 2019. In an interview with the Wisconsin State Journal’s Judy Newman, FluGen CEO Paul Radspinner explains, “That doesn’t sound really fast to people, but if you’ve been in this business, five years to get to FDA approval is rocket speed!” FluGen co-founder and newly inducted National Academy of Sciences member Yoshihiro Kawaoka concurs, “REDEE FLU™ is a result of over 75 years of combined scientific experience in molecular virology, infectious diseases, and “reverse genetics, which has enabled us to not only understand the virus, but to design a better defense against it.”
FluGen has already raised $10M in investment funds since its 2007 start and will seek a follow up round late summer 2013. We pride ourselves on our ability to exceed our investors’ expectations through:
- Lean operations and outstanding financial management
- Transparency and communication
- Accessibility and engagement
To explore investment opportunities in FluGen’s fast-tracking REDEE FLU™, contact President and CEO Paul Radspinner for more information.